Publications by authors named "Tomas Odergren"

Claim this Profile
E
Exidavnemab binds to aggregated α-synuclein in human brains affected by α-synucleinopathies.
Olof Zachrisson, Malin Johannesson, Linda Söderberg, Fredrik Eriksson, Dan Sunnemark, Tomas Odergren

Neurotherapeutics· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, Tolerability, and Pharmacokinetics of Single Doses of Exidavnemab (BAN0805), an Anti-α-Synuclein Antibody, in Healthy Western, Caucasian, Japanese, and Han Chinese Adults.
Emma Boström, Sagar S Bachhav, Hao Xiong, Cindy Zadikoff, Qingbo Li, Tomas Odergren

J Clin Pharmacol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Elevated soluble amyloid beta protofibrils in Down syndrome and Alzheimer's disease.
Malin Johannesson, Charlotte Sahlin, Linda Söderberg, Hans Basun, Johanna Fälting, Tomas Odergren

Mol Cell Neurosci· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of monomeric and soluble aggregated Aβ in Down's syndrome and Alzheimer's disease brains.
Eleni Gkanatsiou, Charlotte Sahlin, Erik Portelius, Malin Johannesson, Linda Söderberg, Tomas Odergren

Neurosci Lett· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population pharmacokinetic modelling and estimation of dosing strategy for NXY-059, a nitrone being developed for stroke.
Siv Jönsson, Yi-Fang Cheng, Charlotte Edenius, Kennedy R Lees, Tomas Odergren

Clin Pharmacokinet· February 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early impairment in consciousness predicts mortality after hemispheric ischemic stroke.
Brett L Cucchiara, Scott E Kasner, David A Wolk, Patrick D Lyden, Volker A Knappertz, Tomas Odergren

Crit Care Med· January 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nitrones as neuroprotective agents in cerebral ischemia, with particular reference to NXY-059.
A Richard Green, Tim Ashwood, Tomas Odergren, David M Jackson

Pharmacol Ther· December 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population pharmacokinetics of clomethiazole and its effect on the natural course of sedation in acute stroke patients.
Per-Henrik Zingmark, Marianne Ekblom, Tomas Odergren, Tim Ashwood, Patrick Lyden

Br J Clin Pharmacol· August 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Animal models of stroke: do they have value for discovering neuroprotective agents?
A Richard Green, Tomas Odergren, Tim Ashwood

Trends Pharmacol Sci· August 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and sedative effects in healthy subjects and subjects with impaired liver function after continuous infusion of clomethiazole.
Carina Centerholt, Marianne Ekblom, Tomas Odergren, Olof Borgå, Gabriela Popescu

Eur J Clin Pharmacol· June 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics in renally impaired subjects of NXY-059, a nitrone-based, free-radical trapping agent developed for the treatment of acute stroke.
Stig Strid, Olof Borgå, Charlotte Edenius, Karl-Gustav Jostell, Tomas Odergren

Eur J Clin Pharmacol· September 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis